Posted: October 3, 2013 at 11:50 am Last updated: June 27, 2014 3:58 pm
Tuesday saw the wrap up of the 2013 European Society of Medical Oncology (ESMO) conference in Amsterdam, which featured key data from several of the companies covered by the biotech ... Read Full Story »
Posted: August 26, 2013 at 1:59 pm Last updated: August 27, 2013 6:45 am
Questcor Pharmaceuticals Inc. (NASDAQ: QCOR) and Under Armour Inc. (NYSE: UA) may seem to have little to nothing in common on the surface. Questcor is in the pharmaceutical business, while ... Read Full Story »
Posted: August 26, 2013 at 1:29 pm Last updated: August 27, 2013 6:48 am
Any time you see a merger announcement, you see a myriad of press releases pertaining to law firms and lawyers investigating the terms of the deal. This is in one ... Read Full Story »
Amgen Inc. (NASDAQ: AMGN) wants to regain its status as the largest publicly traded biotech in the U.S. The company formalized a buyout of cancer drug maker Onyx Pharmaceuticals Inc. (NASDAQ: ... Read Full Story »
If you have analyzed the myriad earnings reports over the summer of 2013, the trend that you will notice is a lack of revenue growth from most major companies. Many ... Read Full Story »
Posted: July 29, 2013 at 8:35 am Last updated: January 29, 2014 10:46 am
Investors and traders are usually on the lookout for new research ideas that will generate higher income or more profits. 24/7 Wall St. reviews many analyst research calls from Wall ... Read Full Story »
Posted: July 22, 2013 at 8:30 am Last updated: January 29, 2014 10:44 am
Investors and traders are usually on the lookout for new research ideas that will generate higher income or more profits. 24/7 Wall St. reviews many analyst research calls from Wall ... Read Full Story »
Posted: July 3, 2013 at 8:10 am Last updated: December 20, 2013 9:35 am
When we screen stocks at the Wall Street firms we cover, we always are anxious to provide our readers with the stocks that the top firms feel have the most ... Read Full Story »
Posted: July 2, 2013 at 8:45 am Last updated: December 20, 2013 9:37 am
On Friday after the market closed, biotech giant Amgen Inc. (NASDAQ: AMGN) made an unsolicited $120 per share bid for Onyx Pharmaceuticals Inc. (NASDAQ: ONXX) that was rejected. The company ... Read Full Story »
Although Amgen Inc.’s (NASDAQ: AMGN) $10 billion offer for Onyx Pharmaceuticals Inc. (NASDAQ: ONXX) was unsolicited and not exactly a stalking horse bid, that’s what many observers expect to be ... Read Full Story »
July 1, 2013: U.S. equity markets opened higher this morning after a blast of economic data from both Asia and Europe. In China, June manufacturing PMI slid lower. Japan’s economics ... Read Full Story »
Cancer-drug developer Onyx Pharmaceuticals Inc. (NASDAQ: ONXX) issued a terse press release yesterday, saying it had “received and rejected” a buyout offer from Amgen Inc. (NASDAQ: AMGN) for $120 per ... Read Full Story »
Posted: June 13, 2013 at 8:15 am Last updated: December 20, 2013 9:58 am
The higher the market climbs, the harder it becomes for investors to find solid stock ideas to add or scale in to their portfolios. With the market currently teetering on ... Read Full Story »
Posted: May 16, 2013 at 7:30 am Last updated: December 20, 2013 10:25 am
The world of biotech investing is always a difficult one. Often a binary event, such as a Food and Drug Administration (FDA) approval or a life-saving capital raise is the ... Read Full Story »
Posted: May 15, 2013 at 8:10 am Last updated: December 20, 2013 10:25 am
Biotech has strongly outperformed the S&P 500 since January of 2011. The NASDAQ Biotechnology Index (NBI) is up 90%, and the AMEX Biotechnology index (BTK) is up 50%, versus the ... Read Full Story »